BMC cancer · 2026
The clinical and psychosocial consequences of genomic Multi-Cancer Detection (MCD) tests in underserved populations: a scoping review.
СтатьяScoping ReviewНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Low Esther, Gayathri Shritha, Wicker Alexandra, Courtright-Lim Amanda, Austin Jessica, Samadder Jewel, Ressler Steven, Tilburt Jon
Аннотация
INTRODUCTION: Multi-cancer detection (MCD) tests currently being tested in clinical trials may be a scalable, convenient means to improve cancer screening, yet little is known about the potential clinical and psychosocial consequences of doing so in underserved communities.
OBJECTIVE: To summarize the current literature examining potential clinical and psychosocial outcomes and consequences for MCD testing in underserved populations.
METHODS: We searched and then reviewed articles from five databases: PubMed, Embase, Scopus, Web of Science, and Cochrane. For inclusion, studies had to primarily focus on MCD testing within underserved populations. Out of 376 articles identified, 29 met inclusion criteria.
RESULTS: Financial constraints were the most frequently cited barrier (n = 23). 24 articles mentioned clinical consequences and nine mentioned psychosocial consequences, with the most common being lower rates of cancer screening with proven existing recommended tests (n = 10) and emotional stress, worry, and anxiety (n = 11), respectively. Many expressed concerns about underrepresentation in clinical trials.
CONCLUSIONS: The review highlights common potential clinical consequences as well as important factors underserved populations may face if/when MCD testing is implemented in their healthcare. Future prospective studies, experimental and observational, should intentionally include underrepresented patient populations to better understand and address these challenges.
OBJECTIVE: To summarize the current literature examining potential clinical and psychosocial outcomes and consequences for MCD testing in underserved populations.
METHODS: We searched and then reviewed articles from five databases: PubMed, Embase, Scopus, Web of Science, and Cochrane. For inclusion, studies had to primarily focus on MCD testing within underserved populations. Out of 376 articles identified, 29 met inclusion criteria.
RESULTS: Financial constraints were the most frequently cited barrier (n = 23). 24 articles mentioned clinical consequences and nine mentioned psychosocial consequences, with the most common being lower rates of cancer screening with proven existing recommended tests (n = 10) and emotional stress, worry, and anxiety (n = 11), respectively. Many expressed concerns about underrepresentation in clinical trials.
CONCLUSIONS: The review highlights common potential clinical consequences as well as important factors underserved populations may face if/when MCD testing is implemented in their healthcare. Future prospective studies, experimental and observational, should intentionally include underrepresented patient populations to better understand and address these challenges.